
#342 Checkpoint Inhibitors: The power, and adverse effects, of immunotherapy (ACP 2022)
The Curbsiders Internal Medicine Podcast
00:00
What's the Difference Between Infusion Reactions and Non-Hodgkin Lumthoma?
You'll see it less commonly, but very importantly, in hodgkin lumthoma. But i would say that the practising inturnist is going to see this in lung cancer. And then let's not forget melanoma. Melanoma and renal cell have long been understood as emunologically active tumors. The good thing we want to inflame is the cancer. I mean, ta an lead to long term disease control, even cure. What does it actually look like for patients? A wat, what kind of experience do they have receiving these treatments? So molly, it's very different than traditional cemo theraby a, and it's even different then than
Transcript
Play full episode